Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 20/20 | 0.54 |
| ▸ | CCR5 | P51681 | 11/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256079 | 1.00 | CCR2 (0.54) | CCR2CCR5KCNH2 | |
| SCHEMBL3946503 | 0.89 | CCR2 (0.59) | CCR2CCR5KCNH2 | |
| SCHEMBL2784973 | 0.89 | CCR2 (0.59) | CCR2CCR5KCNH2 | |
| SCHEMBL2784969 | 0.89 | CCR2 (0.59) | CCR2CCR5KCNH2 | |
| SCHEMBL2785217 | 0.89 | CCR2 (0.59) | CCR2CCR5KCNH2 | |
| SCHEMBL3946507 | 0.89 | CCR2 (0.59) | CCR2CCR5KCNH2 | |
| SCHEMBL3744325 | 0.85 | CCR2 (0.49) | CCR2CCR5KCNH2 | |
| SCHEMBL3744320 | 0.85 | CCR2 (0.49) | CCR2CCR5KCNH2 | |
| SCHEMBL3253123 | 0.83 | CCR2 (0.49) | CCR2CCR5KCNH2 | |
| SCHEMBL3251001 | 0.83 | CCR2 (0.49) | CCR2CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049519-B9 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2049519-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7687508-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2049519-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008014361-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027080-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027080-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR5, CXCR4, CCR7 | CCR2 5/4885CCR5 1/4885KCNH2 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.